Otsuka says Teva’s REXULTI generic infringes patents

24-02-2022

Otsuka says Teva’s REXULTI generic infringes patents

Morumotto / Shuttershock.com

Otsuka Pharmaceutical has sued Teva Pharmaceuticals, alleging that the company’s planned generic of Otsuka’s REXULTI antipsychotic (brexpiprazole) tablets infringe five of its patents.


Otsuka Pharmaceuticals, REXULTI, Teva Pharmaceuticals, Lundbeck

LSIPR